SCHEMBL7460680

SCHEMBL7460680

Sc1cccc(SCc2ccc3ccccc3n2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CYP2E1 P05181 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2B6 P20813 1/20 0.43
CYP2C19 P33261 1/20 0.43
CYSLTR1 Q9Y271 5/20 0.41
CYSLTR2 Q9NS75 3/20 0.41
PDE10A Q9Y233 2/20 0.41
LTB4R Q15722 1/20 0.39
GPBAR1 Q8TDU6 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PRNP P04156 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7455761 0.83 CYSLTR2 (0.49) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL10546745 0.82 CYSLTR2 (0.50) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL7714637 0.82 CYSLTR1 (0.43) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL9818422 0.79 CYSLTR2 (0.42) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL7456253 0.74 CYSLTR1 (0.49) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL5373500 0.74 CYSLTR2 (0.49) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
Hydrogen Sulfide SCHEMBL9818421 0.73 CYSLTR1 (0.48) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL9719792 0.72 CYP1A2 (0.44) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL7457051 0.72 CYSLTR1 (0.54) CYSLTR1CYSLTR2PDE10AGPBAR1
SCHEMBL2877991 0.71 CYSLTR1 (0.52) CYP1A2CYSLTR1CYSLTR2PDE10AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1030665-A4 THERAPEUTIC USES OF QUINOLINE DERIVATIVES AVENTIS PHARM PROD INC (US) 2002-11-27 EP disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-1030665-A1 THERAPEUTIC USES OF QUINOLINE DERIVATIVES Aventis Pharmaceuticals Products Inc. (US) 2000-08-30 EP disclosed
WO-1999020275-A1 THERAPEUTIC USES OF QUINOLINE DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-04-29 WO disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989004305-A1 QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-05-18 WO disclosed